FabiFlu is the first oral favipiravir-approved medication in India for the treatment of Covid-19, it said in a statement.
Drug firm Glenmark Pharmaceuticals on Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate Covid-19 at a price of about Rs 103 per tablet. The drug will be available as a 200 mg tablet at a maximum retail price (MRP) of Rs 3,500 for a strip of 34 tablets, Glenmark Pharmaceuticals said.
FabiFlu is the first oral favipiravir-approved medication in India for the treatment of Covid-19, it said in a statement. The tablets are being produced by the company at its Baddi facility in Himachal Pradesh. The drug will be available both through hospitals and the retail channel, Glenmark said.
- Health ministry revises Home isolation guidelines for COVID cases: Check new do's and don'ts
- Coronavirus in Haryana, Uttar Pradesh Update: Amit Shah for providing Rapid Antigen Kits to two states
- Coronavirus in India: Difference between number of recoveries, active COVID-19 cases now 1.31 lakh, says health ministry